TQT Study
2
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Tebipenem Pivoxil Hydrobromide Tbpmpihbr
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects
A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects
Research Network
Common Treatments
- Tebipenem Pivoxil Hydrobromide Tbpmpihbr1
- Tetrodotoxin1
- Placebo For Tebipenem Pivoxil Hydrobromide Tbpmpihbr1
- Placebos1
- Moxifloxacin 400mg1
Active Sponsors
- Celerion2
- Spero Therapeutics1
- Wex Pharmaceuticals Inc1